Last reviewed · How we verify
NCT03055429
Enhancing Care of the Aged and Dying in Prisons Ph II
NA trial testing Full Scale Unit in Aging Problems in 241 participants. Completed in 30 April 2019.
30 April 2019
Quick facts
| Lead sponsor | Klein Buendel, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 241 |
| Start date | 1 April 2017 |
| Primary completion | 30 April 2019 |
| Estimated completion | 30 April 2019 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Full Scale Unit
Conditions studied
- Aging Problems — all drugs for Aging Problems →
Sponsor
Klein Buendel, Inc. — full company profile →
Who can join
18 and older, any sex, with Aging Problems. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The mission of corrections is to provide custody, control and care for incarcerated individuals. United States prisons are required by constitutional law to provide adequate care for growing numbers of older inmates who will likely spend their final days in prison. This Phase II project focuses on the correct users accessing correct learning strategies in the correct setting (i.e., interdisciplinary prison staff accessing high quality products designed to educate and lead practice change initiatives within the walls of prisons), by continuing research and development of a learning system that promotes an integrated systems approach to enhancing the care of the aged and dying in prisons.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03055429
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aging Problems
Currently open trials in the same condition.
- NCT07144293 — Improving Physical Ability and Cellular Senescence Elimination in HIV · Phase 2 · active not recruiting
- NCT06511297 — Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort · recruiting
- NCT06175871 — New Clinical Rehabilitation Approach for the Management of Falls Risks · NA · recruiting
- NCT06448052 — Umbilical Cord Mesenchymal Stem Cell for Aging-related Low-grade Inflammation · Phase 1, PHASE2 · active not recruiting
- NCT06124339 — Brain Health Virtual Reality Study · NA · recruiting
Other Klein Buendel, Inc. trials
Trials by the same sponsor.
- NCT07417930 — Hybrid Delivery to Increase Access and Sustainability: Evaluating ezParent Implementation · NA · not yet recruiting
- NCT06894277 — Internet-based Talking About Risk and Adolescent Choices: Health and Emotion Regulation Options · NA · recruiting
- NCT05621044 — Physical Activity Smartphone App for African American Men (FitBros) Ph II · NA · completed
- NCT05618158 — Cancer Prevention for Young Rural Adults · NA · completed
- NCT06235632 — Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03055429 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Klein Buendel, Inc.
- Last refreshed: 6 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03055429.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing